Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

被引：506

作者：

Sharma, Padmanee ^{[1
,2
,3
]}

Wagner, Klaus ^{[4
]}

Wolchok, Jedd D. ^{[3
,5
]}

Allison, James P. ^{[3
,6
,7
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA

[3] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA

[4] Univ Texas MD Anderson Canc Ctr, Div Med, Houston, TX 77030 USA

[5] Mem Sloan Kettering Canc Ctr, Div Melanoma Med Oncol, New York, NY 10065 USA

[6] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10065 USA

[7] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA

来源：

NATURE REVIEWS CANCER | 2011年 / 11卷 / 11期

关键词：

PHASE-II TRIAL; IFN-GAMMA; COMBINATION IMMUNOTHERAPY; ANTITUMOR IMMUNITY; CLINICAL-TRIALS; PEPTIDE VACCINE; T-CELLS; MELANOMA; CTLA-4; BLOCKADE;

D O I：

10.1038/nrc3153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provide clinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit.

引用

页码：805 / 812

页数：8

共 61 条

[41] Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1 [J].

Robbins, Paul F. ;

Morgan, Richard A. ;

Feldman, Steven A. ;

Yang, James C. ;

Sherry, Richard M. ;

Dudley, Mark E. ;

Wunderlich, John R. ;

Nahvi, Azam V. ;

Helman, Lee J. ;

Mackall, Crystal L. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Restifo, Nicholas P. ;

Raffeld, Mark ;

Lee, Chyi-Chia Richard ;

Levy, Catherine L. ;

Li, Yong F. ;

El-Gamil, Mona ;

Schwarz, Susan L. ;

Laurencot, Carolyn ;

Rosenberg, Steven A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07) :917-924

[42] Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [J].

Robert, Caroline ;

Thomas, Luc ;

Bondarenko, Igor ;

O'Day, Steven ;

Weber, Jeffrey ;

Garbe, Claus ;

Lebbe, Celeste ;

Baurain, Jean-Francois ;

Testori, Alessandro ;

Grob, Jean-Jacques ;

Davidson, Neville ;

Richards, Jon ;

Maio, Michele ;

Hauschild, Axel ;

Miller, Wilson H., Jr. ;

Gascon, Pere ;

Lotem, Michal ;

Harmankaya, Kaan ;

Ibrahim, Ramy ;

Francis, Stephen ;

Chen, Tai-Tsang ;

Humphrey, Rachel ;

Hoos, Axel ;

Wolchok, Jedd D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2517-2526

[43] Adoptive cell therapy for the treatment of patients with metastatic melanoma [J].

Rosenberg, Steven A. ;

Dudley, Mark E. .

CURRENT OPINION IN IMMUNOLOGY, 2009, 21 (02) :233-240

[44]

Saenger Yvonne M, 2008, Cancer Immun, V8, P1

[45]

Salgaller ML, 1996, CANCER RES, V56, P4749

[46] Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy [J].

Schreibelt, Gerty ;

Tel, Jurjen ;

Sliepen, Kwinten H. E. W. J. ;

Benitez-Ribas, Daniel ;

Figdor, Carl G. ;

Adema, Gosse J. ;

de Vries, I. Jolanda M. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (10) :1573-1582

[47] gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma [J].

Schwartzentruber, Douglas J. ;

Lawson, David H. ;

Richards, Jon M. ;

Conry, Robert M. ;

Miller, Donald M. ;

Treisman, Jonathan ;

Gailani, Fawaz ;

Riley, Lee ;

Conlon, Kevin ;

Pockaj, Barbara ;

Kendra, Kari L. ;

White, Richard L. ;

Gonzalez, Rene ;

Kuzel, Timothy M. ;

Curti, Brendan ;

Leming, Phillip D. ;

Whitman, Eric D. ;

Balkissoon, Jai ;

Reintgen, Douglas S. ;

Kaufman, Howard ;

Marincola, Francesco M. ;

Merino, Maria J. ;

Rosenberg, Steven A. ;

Choyke, Peter ;

Vena, Don ;

Hwu, Patrick .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (22) :2119-2127

[48] Epitope landscape in breast and colorectal cancer [J].

Segal, Neil H. ;

Parsons, D. Williams ;

Peggs, Karl S. ;

Velcutlescu, Victor ;

Kinzler, Ken W. ;

Vogelstein, Bert ;

Allison, James P. .

CANCER RESEARCH, 2008, 68 (03) :889-892

[49] IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity [J].

Shankaran, V ;

Ikeda, H ;

Bruce, AT ;

White, JM ;

Swanson, PE ;

Old, LJ ;

Schreiber, RD .

NATURE, 2001, 410 (6832) :1107-1111

[50] The consensus coding sequences of human breast and colorectal cancers [J].

Sjoeblom, Tobias ;

Jones, Sian ;

Wood, Laura D. ;

Parsons, D. Williams ;

Lin, Jimmy ;

Barber, Thomas D. ;

Mandelker, Diana ;

Leary, Rebecca J. ;

Ptak, Janine ;

Silliman, Natalie ;

Szabo, Steve ;

Buckhaults, Phillip ;

Farrell, Christopher ;

Meeh, Paul ;

Markowitz, Sanford D. ;

Willis, Joseph ;

Dawson, Dawn ;

Willson, James K. V. ;

Gazdar, Adi F. ;

Hartigan, James ;

Wu, Leo ;

Liu, Changsheng ;

Parmigiani, Giovanni ;

Park, Ben Ho ;

Bachman, Kurtis E. ;

Papadopoulos, Nickolas ;

Vogelstein, Bert ;

Kinzler, Kenneth W. ;

Velculescu, Victor E. .

SCIENCE, 2006, 314 (5797) :268-274

← 1 2 3 4 5 6 7 →